公开(公告)号：US20230219968A1

公开(公告)日：2023-07-13

申请号：US18176647

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhem ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klunder

IPC: C07D487/14 ,  A61K9/00 ,  A61K47/12 ,  A61K31/4985 ,  A61K47/38

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K47/12 ,  A61K31/4985 ,  A61K47/38 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20210361647A1

公开(公告)日：2021-11-25

申请号：US17115833

申请日：2020-12-09

Applicant: AbbVie Inc.

Inventor： Roopal B. Thakkar ,  Steven Jungerwirth ,  Ana Paula Machado de Lacerda ,  Ann M. Robinson ,  Jose Jeffrey V. Enejosa ,  Aileen L. Pangan ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klunder ,  Ayman D. Allian

IPC: A61K31/4985 ,  A61K31/495 ,  A61P1/00 ,  A61K9/00 ,  A61K9/48

Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.